Other Posts
LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Kevin Knopf, Dr. Aaron Goodman, and Dr. Jordan Gauthier discuss the practice-changing impact of ASCO presentations in DLBCL.
On June 7, 2021, LARVOL hosted an Oncology Panel to discuss the top diffuse large B-cell lymphoma (DLBCL) clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8, 2021. Dr. Kevin Knopf from the University of California, San Francisco moderated the discussion between hematology KOLs Dr. Aaron Goodman from the University of California, San Diego and Dr. Jordan Gauthier from Fred Hutchinson Cancer Center.
The discussion covered ASCO abstract #7513 Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), ASCO abstract #7540: First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R‑CHOP in patients with newly diagnosed DLBCL, and ASCO abstract #7512 Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
Watch this video for the full discussion:
Our ASCO Panel Series covered six therapeutic areas including DLBCL. Click below to read more about them and watch their video analysis.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
